Clinicians need up-to-date information about when and how to use molecular assays to inform individual patient risk; the side effects of ADT and management options for these side effects; and the results of recent clinical trials in the non-metastatic CRPC setting, so that patients can receive optimal care and delay the onset of metastases as long as possible.